505
Participants
Start Date
February 19, 2020
Primary Completion Date
April 7, 2022
Study Completion Date
February 19, 2023
Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Placebo
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Hs0003 50235, New York
Hs0003 50147, Hershey
Hs0003 50151, Chapel Hill
Hs0003 50210, Atlanta
Hs0003 50280, Watkinsville
Hs0003 50153, Ormond Beach
Hs0003 50141, Tampa
Hs0003 50140, Birmingham
Hs0003 50142, Nashville
Hs0003 50425, Murray
Hs0003 50138, Columbus
Hs0003 50177, Cincinnati
Hs0003 50194, Omaha
Hs0003 50204, Tulsa
Hs0003 50166, Dallas
Hs0003 50201, Arlington
Hs0003 50149, San Antonio
Hs0003 50175, Phoenix
Hs0003 50208, Las Vegas
Hs0003 50161, Los Angeles
Hs0003 50220, San Diego
Hs0003 50270, Seattle
Hs0003 50205, North Miami Beach
Hs0003 50198, Beverly
Hs0003 50146, Boston
Hs0003 50137, East Windsor
Hs0003 50008, Johnston
Hs0003 50180, Providence
Hs0003 30015, Campbelltown
Hs0003 30016, Carlton
Hs0003 30011, East Melbourne
Hs0003 30017, Kogarah
Hs0003 30012, Woolloongabba
Hs0003 40004, Brussels
Hs0003 40121, Brussels
Hs0003 40002, Leuven
Hs0003 40060, Liège
Hs0003 50233, Barrie
Hs0003 50190, Richmond Hill
Hs0003 50192, Saskatoon
Hs0003 50173, St. John's
Hs0003 50133, Surrey
Hs0003 40127, Aarhus N
Hs0003 40197, Amiens
Hs0003 40342, Angers
Hs0003 40355, Le Mans
Hs0003 40132, Nice
Hs0003 40318, Rouen
Hs0003 40246, Saint-Mandé
Hs0003 40285, Toulon
Hs0003 40325, Berlin
Hs0003 40248, Bochum
Hs0003 40327, Bonn
Hs0003 40288, Darmstadt
Hs0003 40324, Dresden
Hs0003 40249, Kiel
Hs0003 40357, Magdeburg
Hs0003 40174, Mainz
Hs0003 40323, München
Hs0003 40177, Münster
Hs0003 40251, Athens
Hs0003 40253, Athens
Hs0003 40252, Thessaloniki
Hs0003 20089, Haifa
Hs0003 20088, Tel Aviv
Hs0003 40261, Catania
Hs0003 40257, Roma
Hs0003 40263, Roma
Hs0003 40258, Rozzano
Hs0003 40331, Terracina
Hs0003 40330, Torino
Hs0003 40351, Breda
Hs0003 40292, Groningen
Hs0003 40264, Rotterdam
Hs0003 40332, Trondheim
Hs0003 40266, Badalona
Hs0003 40294, Las Palmas de Gran Canaria
Hs0003 40295, Pontevedra
Hs0003 40049, Seville
Hs0003 40230, Valencia
Hs0003 40337, Bern
Hs0003 40406, Geneva
Hs0003 40053, Ankara
Hs0003 40270, Antalya
Hs0003 40273, Gaziantep
Hs0003 40050, Istanbul
Hs0003 40272, Istanbul
Hs0003 40271, Izmir
UCB Biopharma SRL
INDUSTRY